347 related articles for article (PubMed ID: 28153556)
1. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections.
Brinda BJ; Pasikhova Y; Quilitz RE; Thai CM; Greene JN
J Hosp Infect; 2017 Apr; 95(4):426-432. PubMed ID: 28153556
[TBL] [Abstract][Full Text] [Related]
2. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
Bishop EJ; Tiruvoipati R; Metcalfe J; Marshall C; Botha J; Kelley PG
Intern Med J; 2018 Jun; 48(6):651-660. PubMed ID: 29363242
[TBL] [Abstract][Full Text] [Related]
3. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
Di Bella S; Nisii C; Petrosillo N
Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
[TBL] [Abstract][Full Text] [Related]
4. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
6. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
El-Herte RI; Baban TA; Kanj SS
Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline for severe Clostridium difficile infection.
Thomas A; Khan F; Uddin N; Wallace MR
Int J Infect Dis; 2014 Sep; 26():171-2. PubMed ID: 25064460
[TBL] [Abstract][Full Text] [Related]
8. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
[TBL] [Abstract][Full Text] [Related]
9. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
[TBL] [Abstract][Full Text] [Related]
10. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Herpers BL; Vlaminckx B; Burkhardt O; Blom H; Biemond-Moeniralam HS; Hornef M; Welte T; Kuijper EJ
Clin Infect Dis; 2009 Jun; 48(12):1732-5. PubMed ID: 19435431
[TBL] [Abstract][Full Text] [Related]
11. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients.
Metan G; Türe Z; Kaynar L; Berk E; Gürsoy Ş; Alp E; Kılıç H; Çetin M
J Chemother; 2015; 27(6):354-7. PubMed ID: 25407220
[No Abstract] [Full Text] [Related]
13. Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report.
Knafl D; Winhofer Y; Lötsch F; Weisshaar S; Steininger C; Burgmann H; Thalhammer F
J Hosp Infect; 2016 Mar; 92(3):296-8. PubMed ID: 26810610
[No Abstract] [Full Text] [Related]
14. Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection.
Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Pelemis M; Delic D; Prostran M; Milosevic I
J Infect Dev Ctries; 2015 Oct; 9(10):1062-7. PubMed ID: 26517480
[TBL] [Abstract][Full Text] [Related]
15. Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection.
Brumley PE; Malani AN; Kabara JJ; Pisani J; Collins CD
J Antimicrob Chemother; 2016 Mar; 71(3):836-40. PubMed ID: 26661392
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
Bass SN; Bauer SR; Neuner EA; Lam SW
J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
[TBL] [Abstract][Full Text] [Related]
17. Is Clostridium difficile infection a risk factor for subsequent bloodstream infection?
Ulrich RJ; Santhosh K; Mogle JA; Young VB; Rao K
Anaerobe; 2017 Dec; 48():27-33. PubMed ID: 28669864
[TBL] [Abstract][Full Text] [Related]
18. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.
Vargo CA; Bauer KA; Mangino JE; Johnston JE; Goff DA
Pharmacotherapy; 2014 Sep; 34(9):901-9. PubMed ID: 24898525
[TBL] [Abstract][Full Text] [Related]
19. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of Clostridium difficile infection (CDI) in a community hospital.
Daniel A; Rapose A
J Infect Public Health; 2015; 8(2):155-60. PubMed ID: 25301221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
